321 related articles for article (PubMed ID: 25362717)
1. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations.
Ogdie A; Schwartzman S; Eder L; Maharaj AB; Zisman D; Raychaudhuri SP; Reddy SM; Husni E
J Rheumatol; 2014 Nov; 41(11):2315-22. PubMed ID: 25362717
[TBL] [Abstract][Full Text] [Related]
2. New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.
Yan D; Blauvelt A; Dey AK; Golpanian RS; Hwang ST; Mehta NN; Myers B; Shi ZR; Yosipovitch G; Bell S; Liao W
J Invest Dermatol; 2021 Oct; 141(10):2328-2337. PubMed ID: 33888321
[TBL] [Abstract][Full Text] [Related]
3. Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project.
Singla S; Ribeiro A; Torgutalp M; Mease PJ; Proft F
RMD Open; 2024 Jan; 10(1):. PubMed ID: 38191215
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the management of psoriatic arthritis: practical considerations.
Harrison SR; Aung Din BNR; Marzo-Ortega H; Helliwell PS
Pol Arch Intern Med; 2024 Jan; 134(1):. PubMed ID: 38164520
[TBL] [Abstract][Full Text] [Related]
5. Automated mass screening and association rules analysis for comorbidities of psoriasis: A population-based case-control study.
Kim BR; Lee KH; Paik K; Kim M; Bae JM; Choi CW; Youn SW
J Dermatol; 2024 Apr; 51(4):539-551. PubMed ID: 38345288
[TBL] [Abstract][Full Text] [Related]
6. Comorbidities in Patients with Psoriatic Arthritis.
Haddad A; Zisman D
Rambam Maimonides Med J; 2017 Jan; 8(1):. PubMed ID: 28178440
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis Comorbidities and Their Treatment Impact.
Taliercio M; Lebwohl M
Dermatol Clin; 2024 Jul; 42(3):405-416. PubMed ID: 38796272
[TBL] [Abstract][Full Text] [Related]
8. Exploration beyond osteoarthritis: the association and mechanism of its related comorbidities.
Li B; Yang Z; Li Y; Zhang J; Li C; Lv N
Front Endocrinol (Lausanne); 2024; 15():1352671. PubMed ID: 38779455
[TBL] [Abstract][Full Text] [Related]
9. Recognizing and managing comorbidities in psoriatic arthritis.
Ogdie A; Schwartzman S; Husni ME
Curr Opin Rheumatol; 2015 Mar; 27(2):118-26. PubMed ID: 25603040
[TBL] [Abstract][Full Text] [Related]
10. Comorbidities in Psoriatic Arthritis.
Husni ME
Rheum Dis Clin North Am; 2015 Nov; 41(4):677-98. PubMed ID: 26476226
[TBL] [Abstract][Full Text] [Related]
11. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Coates LC; Kavanaugh A; Mease PJ; Soriano ER; Laura Acosta-Felquer M; Armstrong AW; Bautista-Molano W; Boehncke WH; Campbell W; Cauli A; Espinoza LR; FitzGerald O; Gladman DD; Gottlieb A; Helliwell PS; Husni ME; Love TJ; Lubrano E; McHugh N; Nash P; Ogdie A; Orbai AM; Parkinson A; O'Sullivan D; Rosen CF; Schwartzman S; Siegel EL; Toloza S; Tuong W; Ritchlin CT
Arthritis Rheumatol; 2016 May; 68(5):1060-71. PubMed ID: 26749174
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative.
Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
J Rheumatol; 2015 Oct; 42(10):1767-80. PubMed ID: 26178281
[TBL] [Abstract][Full Text] [Related]
13. Treating to target in psoriatic arthritis.
Coates LC
Curr Opin Rheumatol; 2015 Mar; 27(2):107-10. PubMed ID: 25603035
[TBL] [Abstract][Full Text] [Related]
14. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
Gossec L; Coates LC; de Wit M; Kavanaugh A; Ramiro S; Mease PJ; Ritchlin CT; van der Heijde D; Smolen JS
Nat Rev Rheumatol; 2016 Dec; 12(12):743-750. PubMed ID: 27829672
[TBL] [Abstract][Full Text] [Related]
15. New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. Food and Drug Administration.
Felquer ML; Soriano ER
Curr Opin Rheumatol; 2015 Mar; 27(2):99-106. PubMed ID: 25633241
[TBL] [Abstract][Full Text] [Related]
16. Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept.
Giunta A; Babino G; Manetta S; Mazzotta A; Chimenti S; Esposito M
Drug Dev Res; 2014 Nov; 75 Suppl 1():S27-30. PubMed ID: 25381970
[TBL] [Abstract][Full Text] [Related]
17. Psoriatic arthritis for the dermatologist.
Tintle SJ; Gottlieb AB
Dermatol Clin; 2015 Jan; 33(1):127-48. PubMed ID: 25412788
[TBL] [Abstract][Full Text] [Related]
18. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
19. Treatment satisfaction of patients with psoriasis.
Schaarschmidt ML; Kromer C; Herr R; Schmieder A; Goerdt S; Peitsch WK
Acta Derm Venereol; 2015 May; 95(5):572-8. PubMed ID: 25394584
[TBL] [Abstract][Full Text] [Related]
20. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
